Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice

2015/08/08 by Sander Kooijman, Yanan Wang, Edwin T. Parlevliet +7 · 138 citations
Chemistry · Medicine · #Adipokines, Inflammation, and Metabolic Diseases #Adipose Tissue and Metabolism #Adipose tissue #Biology #Brown adipose tissue #Cardiovascular Disease and Adiposity #Chemistry #Diabetes mellitus #Endocrinology #Glucagon-like peptide-1 #Insulin #Internal medicine #Lipogenesis #Medicine #Receptor #Thermogenesis #Thermogenin #Type 2 diabetes #White adipose tissue

paper · pdf · doi:10.1007/s00125-015-3727-0

published in Diabetologia 58(11), 2637-2646 (Springer Science+Business Media)

openalex publication_date 2015/08/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

AIMS/HYPOTHESIS: Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, used in the treatment of type 2 diabetes, has recently been shown to increase thermogenesis via the brain. As brown adipose tissue (BAT) produces heat by burning triacylglycerol (TG) and takes up glucose for de novo lipogenesis, the aim of this study was to evaluate the potential of chronic central GLP-1R activation by exendin-4 to facilitate clearance of lipids and glucose from the circulation by activating BAT. METHODS: Lean and diet-induced obese (DIO) C57Bl/6J mice were used to explore the effect of a 5 day intracerebroventricular infusion of the GLP-1 analogue exendin-4 or vehicle on lipid and glucose uptake by BAT in both insulin-sensitive and insulin-resistant conditions. RESULTS: Central administration of exendin-4 in lean mice increased sympathetic outflow towards BAT and white adipose tissue (WAT), resulting in increased thermogenesis as evidenced by increased uncoupling protein 1 (UCP-1) protein levels and decreased lipid content, while the uptake of TG-derived fatty acids was increased in both BAT and WAT. Interestingly, in DIO mice, the effects on WAT were blunted, while exendin-4 still increased sympathetic outflow towards BAT and increased the uptake of plasma TG-derived fatty acids and glucose by BAT. These effects were accompanied by increased fat oxidation, lower plasma TG and glucose concentrations, and reduced body weight. CONCLUSIONS/INTERPRETATION: Collectively, our results suggest that BAT activation may be a major contributor to the glucose- and TG-lowering effects of GLP-1R agonism.

Cited by

• Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males
• Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
• Brown Adipose Tissue—A Translational Perspective
• The Dichotomous Effect of Chronic Stress on Obesity. [europepmc]
• Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. [europepmc]
• Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. [europepmc]
• Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. [europepmc]
• Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. [europepmc]
• Quercetin Lowers Plasma Triglycerides Accompanied by White Adipose Tissue Browning in Diet-Induced Obese Mice. [europepmc]
• Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. [europepmc]
• Interleukin-6 is important for regulation of core body temperature during long-term cold exposure in mice. [europepmc]
• Hypothalamic AMPK as a Mediator of Hormonal Regulation of Energy Balance. [europepmc]
• Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. [europepmc]
• GLP-1 Receptor Agonists and Kidney Protection. [europepmc]
• NTCP deficiency in mice protects against obesity and hepatosteatosis. [europepmc]
• A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. [europepmc]
• Glucagon, GLP-1 and Thermogenesis. [europepmc]
• Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. [europepmc]
• A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure. [europepmc]
• The Role of AMPK Signaling in Brown Adipose Tissue Activation. [europepmc]
• Non-shivering Thermogenesis Signalling Regulation and Potential Therapeutic Applications of Brown Adipose Tissue. [europepmc]
• Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue. [europepmc]
• Browning Epicardial Adipose Tissue: Friend or Foe? [europepmc]
• GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. [europepmc]
• Brown Adipose Tissue-A Translational Perspective. [europepmc]
• FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. [europepmc]
• Dietary butyrate ameliorates metabolic health associated with selective proliferation of gut Lachnospiraceae bacterium 28-4. [europepmc]
• GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. [europepmc]

Related

• Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males
• The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
• Gut-Derived GLP-1 Released by Rare Sugar d -Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity
• Hormonal regulation of human adipose tissue lipolysis: impact of adipose GIP system in overweight and obesity
• How May GIP Enhance the Therapeutic Efficacy of GLP-1?